Cargando…

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are the standard of care for HR-positive/HER2-negative advanced breast cancer patients. However, their role in the treatment of brain metastases is currently unclear. We retrospectively evaluate the results of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubeczko, Marcin, Jarząb, Michał, Krzywon, Aleksandra, Gräupner, Donata, Polakiewicz-Gilowska, Anna, Gabryś, Dorota
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004463/ https://www.ncbi.nlm.nih.gov/pubmed/36902831 http://dx.doi.org/10.3390/jcm12052044

Ejemplares similares

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer
por: Kubeczko, Marcin, et al.
Publicado: (2023)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
por: Bosacki, Claire, et al.
Publicado: (2020)

Chemotherapy for gastric cancer patients – time for personalization in medicine?
por: Nowara, Elżbieta, et al.
Publicado: (2012)

Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023)

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases
por: Luo, Shuimei, et al.
Publicado: (2015)

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
por: Lubanska, Dorota, et al.
Publicado: (2017)

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
por: Matsui, Jennifer K., et al.
Publicado: (2022)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
por: Main, Sasha C., et al.
Publicado: (2022)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature
por: David, Steven, et al.
Publicado: (2020)

Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature
por: Franco, Rejane, et al.
Publicado: (2023)

Association of Genetic Variants in ANGPT/TEK and VEGF/VEGFR with Progression and Survival in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy or Radiochemotherapy
por: Butkiewicz, Dorota, et al.
Publicado: (2020)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Advances in radiotherapy for brain metastases
por: Gondi, Vinai, et al.
Publicado: (2021)

Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases
por: Porte, Judith, et al.
Publicado: (2022)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases
por: Księżniak-Baran, Dorota, et al.
Publicado: (2015)

The Metabolic Footprint of Systemic Effects in the Blood Caused by Radiotherapy and Inflammatory Conditions: A Systematic Review
por: Jelonek, Karol, et al.
Publicado: (2023)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
por: Dang, Fabin, et al.
Publicado: (2021)

Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer
por: Shikanai, Ayana, et al.
Publicado: (2022)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
por: Sun, Chao-Yue, et al.
Publicado: (2022)

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer
por: Kukulska, Aleksandra, et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases
por: Rada, Miran, et al.
Publicado: (2023)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qopqqts0sbiaeenq217gro64m3